FMP
Avenue Therapeutics, Inc.
ATXI
NASDAQ
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
1.86 USD
0.12 (6.45%)
Valuation Date:
Dec 26, 2024 4:00 PM
Share Price on Valuation Date
$1.86
Stock Beta
-0.179
Shares Outstanding
2053920